⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 29, 2024The ProstateOpen Access

Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients

Mike Wenzel Benedikt Hoeh Fabienne Hurst Florestan Koll Cristina Cano Garcia Clara Humke Thomas Steuber Derya Tilki Miriam Traumann Séverine Banek Felix K. H. Chun Philipp Mandel

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the impact of prostate-specific antigen (PSA) nadir, PSA response and time to PSA nadir (TTN) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) in the era of combination therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wenzel et al. (2024) studied this question.

synapsesocial.com/papers/68e67cc7b6db643587606d42 https://doi.org/10.1002/pros.24754

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment2024 · 6 citations
2Predictive Role of PSA Kinetics in Oncological Outcomes of Metastatic Castration-sensitive Prostate CancerOriginal Research · 2026
3Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysisMeta-Analysis · 2026
4Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or EnzalutamideCohort Study · 2026 · 2 citations
5Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadirCohort Study · 2026

More related papers

Remission Depth in Metastatic Hormone-Sensitive Prostate Cancer Is Associated With Prognosis in Patients With Initial Prostate-Specific Antigen Values Above 100 Ng/ML2024
Early prostate specific antigen response and overall survival in metastatic hormone sensitive prostate cancer: Real-world data on age, body mass index, and treatment.2026
Genomic and transcriptomic correlates of deep PSA response in patients with metastatic hormone-sensitive prostate cancer (mHSPC).2026

More from The Prostate

Hippo Pathway Modulation Alters the Proteome and Migratory Phenotype of Prostate Cancer CellsThu,
Identification of Novel CD52 + Fibroblasts in Nodular Prostatic HyperplasiaTue,